Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Tian (Nanjing, China), X. Gui (Nanjing, China), H. Li (Nanjing, China), J. Ding (Nanjing, China), Y. Liu (Nanjing, China), Y. Wang (Nanjing, China), J. Dai (Nanjing, China), H. Cai (Nanjing, China). Serum CC16 is a potential predictor for IPF diagnosis and prognosis. 816

Member's Comments

No comment yet.

Related content which might interest you: Serum biomarkers in SSc-ILD: association with presence, severity and prognosis Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis Source: Eur Respir J , 49 (2) 1501924; DOI: 10.1183/13993003.01924-2015 Year: 2017 Is YKL-40 a prognostic marker in sarcoidosis? Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 The serum YKL-40 is a useful biomarker for asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Circulating total leptin as a diagnostic and prognostic biomarker in sepsis Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure Year: 2019 KL-6 compared to LDH as a prognostic factor in Caucasian patients with idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Serum markers of IPF Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases Year: 2004 The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017 Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis Source: International Congress 2017 – Silicosis has not gone away Year: 2017 Visfatin as a possible serum biomarker in COPD Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases Year: 2019 Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017 Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017 High level of serum SP-D with normal range of KL-6 predicts a good prognosis of patients with fibrotic changes on HRCT Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Serum endostatin is a novel marker for COPD associated to lung function decline and exacerbation Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Prognostic role of CCL18 serum concentrations in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007